01 August 2014

Bayer Animal Health sees positive sales in Q2 2014

The Bayer Group was again successful in the second quarter of 2014. Sales of the Bayer Group rose by 0.9% in the second quarter to EUR 10,458 million (Q2 2013: EUR 10,360). Adjusted for currency and portfolio effects, sales advanced by 6,3%. EBIT rose by 14.5% to EUR 1.473 million (Q2 2013: EUR 1.287 million). 

Gross cash flow in the second quarter of 2014 advanced by 1.5% to EUR 1,705 million (Q2 2013: EUR 1,680 million) due to the improvement in EBITDA, while cash flow moved ahead by 4.2% to EUR 1,601 million (Q2 2013: EUR 1,536 million). Net financial debt increased from EUR 9.1 billion on March 31, 2014 to EUR 9.9 billion on June 30, 2014. 

READ MORE: Stockholders Newsletter Second Quarter 2014

Sales of HealthCare rose in the second quarter by 0.9% to EUR 4,485 million (Q2 2013: EUR 4,800 million). The Animal Health business developed positively with 5% growth to EUR 362 million (Q2 2013: EUR 358 million). The Seresto™ flea and tick collar contributed to this increase, partly on account of volume gains in the United STates. Sales of the Advantage™ line of flea, tick and worm control products showed a slight decrease. 

READ MORE: Bayer continues positive business development


No comments:

Post a Comment